Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry
Silverberg J, Gooderham M, Bunick C, Calimlim B, Grada A, Muñoz Maldonado Y, Li A, Fergestrom N, Simpson E. Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry. SKIN The Journal Of Cutaneous Medicine 2024, 8: s450. DOI: 10.25251/skin.8.supp.450.Peer-Reviewed Original ResearchDermatology Life Quality IndexPP-NRSGlobal Assessment ScaleFollow-up visitAtopic dermatitisQuality of lifeReal-world outcomesSkin clearanceLongitudinal analysisRating ScalePeak Pruritus Numerical Rating ScaleInvestigator Global Assessment scaleSix-month follow-up visitPruritus Numerical Rating ScaleClear/almost clear skinEffect of upadacitinibNon-interventional registryDermatology Life Quality Index scoresNumerical rating scaleAssessment ScaleRegistry of adultsTreating atopic dermatitisEveryday clinical practiceLife Quality IndexImpact of AD
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply